Research programme: urotensin-II receptor antagonists - GlaxoSmithKline

Drug Profile

Research programme: urotensin-II receptor antagonists - GlaxoSmithKline

Alternative Names: SB328872; SB436811; SB657510

Latest Information Update: 19 Apr 2011

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator GlaxoSmithKline
  • Class Pyrrolidines; Sulfonamides
  • Mechanism of Action Urotensin II antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Atherosclerosis; Diabetes mellitus; Heart failure; Hypertension

Most Recent Events

  • 03 Sep 2008 Final pharmacodynamics data from a preclinical trial in Pressure-overload hypertrophy presented at the Congress of the European Society of Cardiology (ESC-2008)
  • 21 Aug 2006 Preclinical trials in Atherosclerosis in United Kingdom (unspecified route)
  • 21 Aug 2006 Preclinical trials in Diabetes mellitus in United Kingdom (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top